Loading clinical trials...

Open-Label Treatment Extension of Protocol MNTX 302 | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Open-Label Treatment Extension of Protocol MNTX 302

A Three-Month Open-Label Treatment Extension of Protocol MNTX 302

NCT01367613•Bausch Health Americas, Inc.

View on ClinicalTrials.gov

Summary

This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Must be enrolled and consented within 28 days of the end of study visit of MNTX 302 and 14 or more days from first dose of study drug in MNTX 302.
•2. Negative pregnancy test
•3. Stable vital signs

Exclusion Criteria

•1. Women who are pregnant and/or nursing
•2. Received any investigational product, other than MNTX, in the past 30 days
•3. Evidence of fecal impaction
•4. Clinically significant active diverticular disease

Locations (1)

Progenics Pharmaceuticals, Inc.

Tarrytown, New York, United States

Key Dates

Start Date

March 1, 2004

Primary Completion Date

January 1, 2006

Completion Date

January 1, 2006

Last Updated

November 27, 2019

Enrollment

ACTUAL participants

Conditions

Terminal Illness

Interventions

SC Methylnaltrexone

DRUG

DigiPall; a Trial of Digital Patient Reported Outcome and Biomarker Monitoring in Palliative Care

NCT06615349

Terminal IllnessTerminal Cancer

View study

NOT_YET_RECRUITING

Mapping Financial Support for the Terminally Ill

NCT06793631

People with Terminal Illness

View study

COMPLETED

iLIVE Volunteer Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 27, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Open-Label Treatment Extension of Protocol MNTX 302

Inclusion Criteria

Exclusion Criteria

DigiPall; a Trial of Digital Patient Reported Outcome and Biomarker Monitoring in Palliative Care

Mapping Financial Support for the Terminally Ill

iLIVE Volunteer Study

Family Talk Intervention in the Context of Specialised Palliative Home Care

Comparing Haloperidol and Olanzapine in Treating Terminal Delirium

Participating in Palliative Care Research